Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


News & Press Releases

Here you will find the most recent organizational news from FARA, including information on events, and awareness and advocacy initiatives. To locate an article from a certain date, please use the archives on the right side of your screen.

Gill Family Wins FARA a Spot on Jimmie Johnson’s Helmet of Hope To Be Worn During NASCAR's Pepsi 500 on August 31, 2008

The Gill Family of Parkville, Missouri wrote a winning essay for the Helmet of Hope contest sponsored by The Jimmie Johnson Foundation to showcase the charity most important to the applicant family. FARA was one of a total of twelve charities selected from the fan submissions and the FARA logo will be displayed on Jimmie's (NASCAR) helmet during the Pepsi 500 on August 31, 2008 at the Auto Club Speedway. Susan Gill, mother of Rachel (FA), enlisted the support of her family to submit essays on why the Friedreich’s Ataxia Research Alliance (FARA) was important to them, and the essay of Rachel’s uncle Neil Hanneman (a former stock car racer) was selected as one of the winning entries. Hanneman writes, “Seeing the FARA logo on Jimmie's helmet would give some visibility to finding a cure for a life- shortening disease that affects children while giving hope and enjoyment to those kids that are afflicted by FA." Watch for the FARA logo on Jimmie’s helmet as the #48 car speeds around the track.

Additional information on FARA and the Helmet of Hope can be found on

Fans may bid on the one-of-a kind, race-worn helmet at The auction runs through Tues., Aug. 26 at 11:40 p.m. ET with proceeds benefiting San Diego Habitat for Humanity.

A Special Ticket Package is Available Through The Johnson Foundation. To Get Info / Purchase Tickets Click: Auto Club Speedway and select Jimmie Johnson Foundation Package, then click More Info.

$250,000 in Kyle Bryant Translational Research Awards Announced Today

The National Ataxia Foundation (NAF) and the Friedreich's Ataxia Research Alliance (FARA) announced today that, this year, they are co-funding two $125,000 Kyle Bryant Awards that are going to promising translational research in Friedreich’s Ataxia (FA).  One award is being made to Repligen Corporation, Waltham MA, who in collaboration with an international team of researchers is advancing compounds called HDAC inhibitors that target increased levels of frataxin – the protein that is severely reduced in FA. The second award goes to a team of investigators at Ohio State University, Drs. Subha V. Raman and Roula al-Dahhak, who propose a series of sophisticated imaging studies to better understand, prevent and treat heart disease in FA.

Repligen’s research proposes to develop methods to use with the FA mouse models in order to select which HDAC inhibitor will be best to test in FA patients and what doses of that HDAC inhibitor will be most likely to maximize frataxin protein levels while minimizing toxicity. Drs. Subha V. Raman and Roula al-Dahhak, recognizing that heart disease in FA is poorly understood, have focused their research project on testing new ideas regarding how heart disease develops in FA, earlier detection of the heart disease, and development of new prevention and treatment strategies that would reduce heart-related disability and death.


The Muscular Dystrophy Association (MDA) and the Friedreich's ataxia Research Alliance (FARA) announced this week that, on July 24, the antioxidant compound idebenone received conditional market approval for the treatment of Friedreich's ataxia (FA) in Canada but failed to obtain such approval in Europe.

Idebenone, which is related to the natural substance coenzyme Q10, was developed by the Swiss pharmaceutical company Santhera as SNT-MC17.

The company is testing the compound, which is intended to improve cellular energy production and reduce oxidative stress, in FA, Duchenne muscular dystrophy (DMD) and Leber’s hereditary optic neuropathy.

In a phase 2 study in patients with FA, idebenone was generally well tolerated and associated with improvement in neurological function, as well as scores measuring activities of daily living.

A phase 3 trial in FA remains open.

First Human Dose Initiated of Promising New Friedreich’s Ataxia Drug Highlights Effectiveness of New Public-Private Partnership Model

The Friedreich’s Ataxia Research Alliance (FARA) joins its public and private partners in announcing that a phase I clinical trial of a promising new drug, designated A0001, began dosing on July 11th. This milestone achievement illustrates the power of a new model for advancing therapies, especially in rare diseases.

“FARA believes in the essential nature of public-private partnerships that involve government agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), academic investigators, the pharmaceutical industry, and multiple non-profits like FARA and the Muscular Dystrophy Association (MDA),” said FARA President Ron Bartek. “FARA is grateful to its partners that span the spectrum from discovery through clinical development as we work together to advance promising compounds like A0001 toward the goal of approved treatments and cures for Friedreich’s Ataxia (FA) and other neurodegenerative disorders.”

Request for Applications

Mitochondrial Therapeutic Approaches Research Award sponsored by Friedreich’s Ataxia Research Alliance and the Muscular Dystrophy Association

The Friedreich’s Ataxia Research Alliance (FARA) an d the Muscular Dystrophy Association (MDA) invite proposals, under a competitive Request for Applications (RFA) process, to award a grant focusing on critical issues or hypotheses that advance therapeutic approaches to mitochondrial dysfunction as it relat es to neurodegenerative diseases. We anticipate funding one award for two years under this program. The total award is limited to $100,000 (indirect costs can not exceed 10%) per year for two years.

Read More: Request for Applications

Page 85 of 93


Event E.jpg

News & Press Archives

Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator